Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | HCK | P08631 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084758 | 0.90 | DGAT2 (0.41) | PDE2AGPR119 | |
| SCHEMBL2084591 | 0.87 | DGAT2 (0.46) | — | |
| SCHEMBL2087398 | 0.85 | PDE4A (0.48) | PDE2AGPR119PDE10APDE4APDE4B | |
| SCHEMBL4120370 | 0.84 | KDR (0.41) | GPR119HCRTR1RPS6KA3LCKHCK | |
| SCHEMBL2055569 | 0.83 | GPR119 (0.38) | PDE2AGPR119PDE10ALCKHCK | |
| SCHEMBL1754252 | 0.82 | PDE4A (0.44) | PDE2APDE10APDE4APDE4BPDE4C | |
| SCHEMBL4115056 | 0.82 | GPR119 (0.41) | GPR119HCRTR1RPS6KA3LCKHCK | |
| SCHEMBL2055567 | 0.82 | GPR119 (0.39) | GPR119HCRTR1RPS6KA3 | |
| SCHEMBL2083966 | 0.82 | GPR119 (0.37) | PDE2AGPR119HCRTR1RPS6KA3 | |
| SCHEMBL2085953 | 0.82 | GPR119 (0.43) | PDE2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| EP-2035427-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-12-11 | — | — | EP | disclosed |
| EP-2520577-A1 | Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | PDE2A 2016/4885GPR119 224/4885PDE10A 967/4885 |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | PDE2A 2496/4885GPR119 190/4885PDE10A 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.